Introduction
Protein kinase C (PKC)' is a gene family consisting of several subfamilies (conventional: a, /3k, 31, y, novel: 6, E, 9, 77; and 1. Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; MDR, multidrug resistant; PKC, protein kinase C; TPA, tetradecanoyl-13-phorbol acetate; vit-tk-CAT, estrogen-responsive vitellogenin promoter-CAT reporter construct.
atypical: X, 4, t) that lie on signal transduction pathways regulating growth and differentiation in a large and diverse group of cell types ( 1, 2) .
A role for members of the PKC gene family in regulating growth and differentiation of breast cancer has been suggested by several separate observations. In extracts prepared from samples derived from patients undergoing breast biopsy, PKC activity was elevated in malignant breast tumors relative to normal breast tissue (3) . In cultured breast cancer cell lines, a positive correlation also existed between PKC activity and the more biologically aggressive estrogen receptor negative phenotype (4, 5) . In the MCF-7 and other breast cancer cell lines, phorbol ester treatment that induced downregulation of PKC activity inhibited growth and enhanced expression of parameters associated with a more differentiated phenotype (6) (7) (8) (9) . Studies examining the effects of bryostatin-1 and tetradecanoyl-13-phorbol acetate (TPA) on growth of breast cancer cell lines have implicated a role for the conventional PKC-a isoform in mediating TPA-induced growth inhibition (8) . Desensitization to phorbol ester-induced growth inhibition has been associated with increases in PKC content and activity (6) . Additionally, inhibitors of PKC-associated kinase activity, such as the staurosporine analogue UCN-01, inhibit growth of the MCF-7 cell (10). These findings suggest that aberrations in the PKC signal transduction pathway may be involved in the pathogenesis and/or progression of breast cancer, and that PKC may be involved in the regulation of estrogen receptor expression, a parameter of prognostic and therapeutic importance.
Given the possible role for the PKC signal transduction pathway, specifically PKC-a, in the pathogenesis of breast cancer, we directly examined the effects of stably overexpressing PKC-a on the MCF-7 human breast cancer cell line. Stable overexpression of PKC-a led to an enhanced rate of proliferation, more efficient anchorage-independent growth, dramatic alterations in cellular morphology manifested by loss of an epithelioid appearance with a marked increase in vimentin expression, a marked decrease in estrogen receptor mRNA transcripts and estrogen-dependent gene expression, enhanced tumorigenicity with metastatic capacity when injected into nude mice, and significant increases in the endogenous expression of PKC-/3 accompanied by decreases in the content of PKC-77 and -6.
These findings demonstrate that overexpression of PKCa, either directly or indirectly, possibly via increases in the endogenous expression of PKC-,3 or decreases in the 77 or 6 isoforms, leads to the acquisition of a more fully transformed phenotype in the MCF-7 breast cancer cell, and provide further evidence for a possible role of the PKC signaling pathway in the pathogenesis and/or progression of breast cancer and regulation of estrogen receptor status.
( 1 ) was subcloned into the pSV2M (2) Western blot analysis was done as previously described using antisera specific for the a, /3, c, and 4 isoforms (13, 15) . Antipeptide antiserum against the carboxy terminus of PKC-77 (INQDEFRNFSYV-SPELQL) was prepared and used in this study at a dilution of 1:1,000. This antiserum recognized a protein doublet at approximately the predicted molecular weight for PKC-77 and a slightly lower molecular weight species. The specificity of these proteins was confirmed by the ability of the immunizing peptide to abolish detection of these bands. A separate PKC-77 antiserum, purchased from Santa Cruz Biotechnology, Inc., (Santa Cruz, CA) gave identical results to those obtained using our 7 antipeptide antibody. Antiserum to PKC-6 was purchased from Transduction Labs (Lexington, KY) and was used as per their recommendations. Detection was performed using goat anti-mouse antiserum and enhanced chemiluminescence (15) . Densitometric analysis of the autoradiograms was performed using a laser densitometer (Ultrascan XL; Pharmacia LKB Biotechnology, Inc., Piscataway, NJ).
Northern blot analysis. RNA was extracted using a single-step acid guanidinium thiocyanate-phenol extraction technique (17) . RNA (20 jig) was electrophoresed, transferred to nylon filters, and hybridized to random primer labeled cDNA probes (18) . Ethidium bromide staining was used to confirm the integrity of the RNA and assess the equivalency of loading. The probes used for PKC-fl, -77, and -6 were isolated by P. Parker [19] ). Growth in soft agar. In a 35-mm dish, 1 ml of 0.6% agar in DME with 10% FCS was plated and allowed to harden. Top agar, 0.36%, containing 103 cells/ml was layered over the hardened agar. Cultures were incubated at 37°C in 5% CO2 for 10-12 d. Colonies > 50 cells were visually enumerated.
Tumor and metastatic evaluation in nude mice. BALB/c nu/nu female mice, 6-8 wk old, were inoculated with 7 x 106 cells in 0.1 ml of PBS into the mammary fat pad. Because of the rapid primary tumor growth in mice inoculated with the MCF-7-PKC-a cells, animals were killed only 4 wk after inoculation. Tumor volume was assessed by measuring tumor size in three dimensions. Histologic examination of the primary tumor and other organs was done using hematoxylin and eosin staining.
Results
Overexpressing of PKC-a increased PKC activity and altered expression of endogenous PKC isofonns. MCF-7 cells were cotransfected with the neomycin resistance plasmid and either the pSV2M(2)6 vector without the insert or containing a fulllength cDNA encoding PKC-a. Cells harboring the neomycin resistance gene were identified by selection in G418. Rather than single cell cloning, a mixed group of neomycin-resistant cells was isolated. A heterogenous population of transfected cells was used to minimize the possible artifacts that can be associated with single cell cloning. Analysis of PKC-a expression is shown in Fig. 1 pression modulated expression of other endogenous PKC family members.
Overexpression of PKC-a drastically altered morphology of the MCF-7 cell. MCF-7-PKC-a cells demonstrated dramatic morphologic alterations as compared to parental MCF-7 cells (Fig. 3) . Parental and vector-transfected MCF-7 cells displayed an epithelioid appearance growing adherent to the plastic surface (Fig. 3, A and B, respectively). In marked contrast, MCF-7-PKC-a cells assumed a spherical shape, could proliferate in suspension, especially as cell density increased, and occasionally formed giant cells (Fig. 3 C) . Electron microscopy indicated that parental MCF-7 cells contained primary lysosomal granules (Fig.  4 A, black triangular indicators), while MCF-7-PKC-a cells contained an abundance of secondary lysosomal granules (Fig.  4 B, thin arrows) . The nuclear to cytoplasmic ratio was significantly greater in MCF-7-PKC-a cells. While not observed in MCF-7 cells, areas enriched in intracellular fibrils were noted in MCF-7-PKC-a cells (Fig. 4 X, thick arrows) . At a magnification of 50,000 these fibrils had a diameter consistent with intermediate filaments (data not shown). As shown in Fig. 4 (4, 5) .
Given this association and the more morphologically aggressive appearance of the MCF-7-PKC-a cell, estrogen receptor status was analyzed (Fig. 5 A) . By Northern blot analysis, parental MCF-7 cells were shown to contain transcripts for estrogen receptor mRNA. In contrast, mRNA transcripts for the estrogen receptor were not detected in MCF-7-PKC-a cells. To assess the functional importance of this finding, expression of estrogenresponsive genes and the activity of an estrogen-responsive genes and the activity of an estrogen-responsive reporter construct were analyzed. Expression of estrogen-responsive genes, pS2, and cathepsin D (23, 24) , were markedly decreased in MCF-7-PKCa cells grown in the presence of 10% FCS (Fig. 5 A) . Activity of the estrogen-responsive vit-tk-CAT reporter construct induced by estrogens contained in 10% FCS was apparent in parental MCF-7 cells (Fig. 5 B) . However, this estrogen-dependent activity was minimal in MCF-7-PKC-a cells. Thus, the MCF-7-PKC-a cells share a similar relationship between decreased estrogen receptor expression and increased PKC activity, as has previously been described in clinical samples from patients with breast cancer (4). MCF-7-PKC-a cells demonstrate a higher proliferative rate and enhanced anchorage-independent growth. MCF-7-PKC-a cells proliferated at a higher rate than did parental or vector-transfected cells (Fig. 6 A) . As MCF-7-PKC-a increased in density, they detached from the plastic surface and proliferated in suspension (Fig. 6 B) . The nonadherent population of the MCF-7-PKC-a were viable as assessed by trypan blue exclusion (data not shown). In contrast, parental MCF-7 cells proliferated in an adherent fashion (Fig. 6 B) . MCF-7-PKC-a and parental or vector-transfected cells reached saturation density at 1.2 x 106/ml and 0.5 X 106/ml, respectively (data not shown). The importance of the higher cell density at confluence in MCF-7-PKC-a cells is somewhat uncertain given the ability of these cells, but not the parental MCF-7 cells, to grow in suspension.
Given the rapid proliferative rate of MCF-7-PKC-a cells and the poor prognostic value in clinical specimens of a high S phase value (25) , the proportion of exponentially growing cells in S phase was evaluated. In parental MCF-7 cells, the cells were proportioned as follows: Go/GI: 61± 1.6; S: 23±1. Student's t test, these differences between the parental MCF-7 and MCF-7-PKC-a cells were statistically significant at a level of <0.05.
MCF-7-PKC-a cells readily grew in an anchorage-independent manner in soft agar (Fig. 7) . However, under these experimental conditions, parental MCF-7 cells displayed negligible anchorage-independent growth with only a few cell clusters observed and no colonies of > 50 cells detected (Fig. 7) .
MCF-7-PKC-a cells were tumorigenic in nude mice with a propensity to metastasize. When injected into the mammary fat pad, MCF-7-PKC-a cells rapidly formed large primary tumors in all mice by 4 wk postinoculation (Table I ). The single mouse that did not form a tumor when inoculated with MCF-7-PKC-a cells was inadvertently injected outside the mammary fat pad and into the subcutaneous space. The tumors in mice inoculated with MCF-7-PKC-a cells were well circumscribed and bordered by a thin fibrous tissue network. Histologically, the MCF-7-PKC-a primary tumors were composed of solid sheets of tightly packed, anaplastic, round to polygonal cells with scant basophilic to pale eosinophilic cytoplasm and mild cellular pleomorphism (Fig. 8, A and B) . Marked nuclear pleomorphism, increased content of nucleoli, and numerous mitotic figures were also noted in the primary MCF-7-PKC-a tumors. In contrast, parental MCF-7 cells formed only microscopic, A negative correlation between PKC activity and estrogen receptor status in breast cancer has been previously noted (4, 5) . The mechanism responsible for this association has yet to be fully elucidated. Exposure of breast cancer cells to phorbol esters that both activate and downregulate PKC activity results in a significant reduction in mRNA transcripts of the estrogen receptor (30) (31) (32) . Given that the status of alterations within the PKC pathway was not evaluated in these investigations (31) (32) (33) , the specific mechanism by which phorbol esters interacted with the PKC pathway to decrease the level of mRNA transcripts for the estrogen receptor gene is unclear. Thus, estrogen receptor expression could be negatively modulated by phorbol ester-induced activation of a specific PKC isoform(s) or because of downregulation of an isoform( s) necessary for maintenance of estrogen receptor mRNA levels. In the MCF-7-PKCa cell, the predominant alterations in the PKC pathway were an increase in the conventional a and isoforms. It is tempting to speculate that the increased content of these isoforms led directly to an enhanced basal kinase activity, which in turn activated a cascade that decreased content of estrogen receptor mRNA transcripts. Given the increased level of PKC-a in the estrogen receptor-negative MCF-7-PKC-a cell and the increased PKC-a levels with a reduction in PKC-,B content in the estrogen receptor-negative, multidrug-resistant (MDR) MCF-7-MDR cells (33), a role for PKC-a in negatively modulating estrogen receptor expression seems possible. Obviously, further studies will need to be undertaken to prove such a hypothesis.
The significant morphologic alterations and higher degree of phenotypic transformation observed in the MCF-7-PKC-a cell contrast with the MCF-7-MDR clones that also overexpress PKC-a. In the MCF-7-MDR subclones, PKC-a overexpression, relative to parental MCF-7 cells, is at least as much as or greater than that seen in MCF-7-PKC-a cells (34) 7-PKC-a cells. Possibly explaining this discrepancy are differences in expression of other PKC isoforms in the MCF-7-PKCa and MCF-7-MDR cells. In MCF-7-MDR cells, PKC-e is undetectable and significant decreases in the /3 and 6 isoforms are detected (34) . In contrast, PKC-/3 expression is enhanced, levels of PKC-6 are only modestly decreased, and PKC-e content is unchanged in MCF-7-PKC-a cells. In addition, content of PKC-iq is markedly decreased in MCF-7-PKC-a cells, and to our knowledge the status of this isoform in MCF-7-MDR has not yet been reported. The decreased PKC-27 content in MCF-7-PKC-a cells. may be related to the less differentiated status of this breast epithelial cell. In other epithelial cell types, a positive correlation exists between the level of PKC-77 expression and a more differentiated epithelial phenotype (35) . Thus, the dissimilar phenotypes displayed by MCF-7-PKC-a and MCF-7-MDR cells could result from the differences in the array of expression of other PKC isoforms or an interplay between the content of an individual PKC isoform or subfamily relative to that of another isoform or subfamily. Alternatively, other phenotypic alterations occurring in the MCF-7-MDR cell resulting from selection in doxorubicin could modify the response of this cell to the elevated levels of PKC-a. This latter possibility is suggested by the finding that overexpression of PKC-a in an MCF-7 cell line that was clonally isolated on the basis of its resistance to doxorubicin was reported to proliferate at approximately the same rate as the parental MCF-7 cell (36).
An alternative explanation for the different phenotype expressed by the MCF-7-PKC-a cell is that exposure to G418 (37, 38) . In hematopoietic cells, increases in the endogenous expression of PKC-a are associated with differentiation and cessation of growth (13) . These divergent effects indicate that alterations in proliferation or differentiation induced by PKC-a overexpression are not an intrinsic property of this isoform, but are modulated by a dynamic interaction between cell-specific and maturationally related factors.
The mechanism by which overexpression of PKC-a alters morphology, enhances proliferation, increases tumorigenicity, and enhances metastatic potential remains to be determined. The increased mass of PKC-a would be predicted to increase the basal level of kinase activation. An enhanced basal level of kinase activation leading to increased phosphorylation of cellular substrates could induce the phenotype observed in the MCF-7-PKC-a cells. However, activation of PKC-a and other endogenous MCF-7 isoforms in the parental MCF-7 cell by either TPA or cell permeant diacylglycerol derivatives causes growth inhibition and differentiation (6) (7) (8) (9) . Thus, if an increase in the basal kinase activity was responsible for the observed changes in the MCF-7-PKC-a cell, then qualitatively different cellular responses are elicited by PKC-associated kinase activity stimulated by autocrine mechanisms or factors contained in serum (e.g., enhanced proliferation in MCF-7-PKC-a cells). Alternatively, PKC-a overexpression may use a kinase-independent mechanism to elicit the phenotypic alterations observed in the MCF-7-PKC-a cell. A kinase-independent mechanism is supported by the temporal association of an increase in an underphosphorylated, kinase-inactive species of PKC-a in TPAtreated MCF-7 cells that have become desensitized to TPAinduced growth inhibition and have resumed proliferation (6) . Therefore, PKC-a overexpression, whether via direct proteinprotein interactions or through a potential association with DNA by the cysteine-rich zinc fingers contained in the C1 domain, has the theoretical potential to elicit signal transduction by a kinase-independent mechanism. Further studies with kinase-defective PKC-a mutants will be required to directly assess this hypothesis. Lastly, the phenotypic alterations in MCF-7-PKCa cells could be due in part to the high level of PKC-#B expression or reduction in PKC-77 and -6 content. Given the low level of #3 expression in the parental cell, the signal transmitted by phorbol ester-induced activation of this isoform would be limited relative to that elicited by stimulation of the other TPAresponsive isoforms (a, 6, 71, and e). Thus, the biologic responses in TPA-treated parental MCF-7 cells would largely reflect activation of the a, 6, rq, and e isoforms. In MCF-7-PKC-a cells, PKC-,/ is highly overexpressed and would be predicted to contribute substantially to the basal level of kinase activity generated by PKC family members, while the contribution from PKC-r1 and -6 would be less. As has been postulated by others ( 1, 2), differences in substrate specificity or subcellular distribution of PKC-,/ could elicit qualitatively dissimilar cellular responses from those induced by the a, 6, i7, and E isoforms. Such differences between isoforms and the high degree of, overexpression with the concomitant reduction in r, and 6 expression in MCF-7-PKC-a cells could provide a possible mechanism explaining the divergent growth and phenotypic characteristics of parental MCF-7 and MCF-7-PKC-a cells.
The anchorage-independent growth of MCF-7-PKC-a cells demonstrates that anoikis that normally occurs upon detachment of epithelial cells from their matrix has been abrogated (39) . A role for the PKC pathway in negatively modulating initiation of anoikis has been previously demonstrated in phorbol estertreated Madin-Darby canine kidney epithelial cells (39 Expression of PKC-/3 was enhanced in the MCF-7-PKCa cell. The human PKC-f promoter contains multiple enhancer elements, including AP-1, AP-2, SpI, E box, and octamer motifs, and also contains a sequence involved in transcriptional silencing (40) . Interestingly, in K562 erythroleukemia cells, both basal and TPA-inducible expression of PKC-,6 only require a sequence containing two SpI sites, an E box, and an octamer motif (40) . Given that the AP-1 and AP-2 sites are not necessary for induction of this gene, it has been postulated that transcriptional activation occurs via a non-AP-1 -dependent mechanism (40) . Consistent with these results, our findings show that TPA treatment for a 24-h period does not increase expression of PKC-/3 mRNA transcripts in parental MCF-7 cells (data not shown). These findings suggest that, in MCF-7-PKC-a cells, induction of PKC-,6 expression occurs either as a direct effect of PKC-a overexpression by a kinase-independent mechanism or secondary to phenotypic changes associated with the MCF-7-PKC-a cell. The factors, and the level at which they act to modulate the endogenous expression of the , f isoform, are under investigation in our laboratories.
The clinical significance of these findings in the prognostic evaluation of malignant breast lesions and in developing novel therapeutic modalities seems promising. Assessing the level and array of specific PKC isoform expression in primary breast masses could be useful in gauging the metastatic potential and/ or biological aggressiveness of the lesion. Such 
